304 related articles for article (PubMed ID: 33545740)
21. Epigenetic alterations and microRNA misexpression in cancer and autoimmune diseases: a critical review.
Saito Y; Saito H; Liang G; Friedman JM
Clin Rev Allergy Immunol; 2014 Oct; 47(2):128-35. PubMed ID: 24362548
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.
Walsh L; Gallagher WM; O'Connor DP; Ní Chonghaile T
Expert Rev Mol Diagn; 2016; 16(5):541-51. PubMed ID: 26895288
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
24. Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy.
Maio M; Covre A; Fratta E; Di Giacomo AM; Taverna P; Natali PG; Coral S; Sigalotti L
Clin Cancer Res; 2015 Sep; 21(18):4040-7. PubMed ID: 26374074
[TBL] [Abstract][Full Text] [Related]
25. The roles of DNA, RNA and histone methylation in ageing and cancer.
Michalak EM; Burr ML; Bannister AJ; Dawson MA
Nat Rev Mol Cell Biol; 2019 Oct; 20(10):573-589. PubMed ID: 31270442
[TBL] [Abstract][Full Text] [Related]
26. Epigenetics and oncology.
Mummaneni P; Shord SS
Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
[TBL] [Abstract][Full Text] [Related]
27. Targeting DNA methylation for epigenetic therapy.
Yang X; Lay F; Han H; Jones PA
Trends Pharmacol Sci; 2010 Nov; 31(11):536-46. PubMed ID: 20846732
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
29. Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors.
Liu Z; Gao Y; Li X
Expert Rev Anticancer Ther; 2019 Feb; 19(2):139-149. PubMed ID: 30470148
[No Abstract] [Full Text] [Related]
30. Rebelled epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy.
Komar D; Juszczynski P
Clin Epigenetics; 2020 Oct; 12(1):147. PubMed ID: 33054831
[TBL] [Abstract][Full Text] [Related]
31. Targeting Epigenetics in Cancer.
Bennett RL; Licht JD
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():187-207. PubMed ID: 28992434
[TBL] [Abstract][Full Text] [Related]
32. Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.
Brien GL; Valerio DG; Armstrong SA
Cancer Cell; 2016 Apr; 29(4):464-476. PubMed ID: 27070701
[TBL] [Abstract][Full Text] [Related]
33. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
Valdespino-Gómez VM; Valdespino-Castillo VE
Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
35. Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy.
Chen F; Shi Y; Zhang J; Liu Q
Curr Drug Targets; 2020; 21(11):1084-1098. PubMed ID: 32410563
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic regulators and their impact on therapy in acute myeloid leukemia.
Pastore F; Levine RL
Haematologica; 2016 Mar; 101(3):269-78. PubMed ID: 26928248
[TBL] [Abstract][Full Text] [Related]
37. Clinical translation of epigenetics in cancer: eN-CORe--a report on the second workshop.
Zelent A; Petrie K; Lotan R; Waxman S; Gore SD
Mol Cancer Ther; 2005 Nov; 4(11):1810-9. PubMed ID: 16276003
[TBL] [Abstract][Full Text] [Related]
38. Deregulated chromatin remodeling in the pathobiology of brain tumors.
Spyropoulou A; Piperi C; Adamopoulos C; Papavassiliou AG
Neuromolecular Med; 2013 Mar; 15(1):1-24. PubMed ID: 23114751
[TBL] [Abstract][Full Text] [Related]
39. The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy.
Liu N; Zhao R; Ma Y; Wang D; Yan C; Zhou D; Yin F; Li Z
Curr Top Med Chem; 2018; 18(28):2380-2394. PubMed ID: 30430946
[TBL] [Abstract][Full Text] [Related]
40. Structural diversity of the epigenetics pocketome.
Cabaye A; Nguyen KT; Liu L; Pande V; Schapira M
Proteins; 2015 Jul; 83(7):1316-26. PubMed ID: 25974248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
